Progression of brain atrophy and cognitive decline in diabetes mellitus: A 3-year follow-up

Neurology

Volumn 75, Issue 11, 2010, Pages 997-1002

  Van Elderen, S G C ^a   De Roos, A ^a   De Craen, A J M ^b   Westendorp, R G J ^b,e   Blauw, G J ^b   Jukema, J W ^c,f   Bollen, E L E M ^d   Middelkoop, H A M ^d   Van Buchem, M A ^a   Van Der Grond, J ^a  

^a Departments of Radiology   (Netherlands)

^b Consortium of Healthy Ageing   (Netherlands)

^c Departments of Cardiology   (Netherlands)

^d Consortium of Healthy Ageing   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Durrer Center for Cardiogenetic Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BRAIN ATROPHY; BRAIN DEGENERATION; BRAIN INFARCTION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; WHITE MATTER; ATROPHY; BRAIN; COGNITION DISORDERS; COMPLICATION; HYPERGLYCEMIA; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; VERY ELDERLY;

ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PRAVASTATIN;

AGED; AGED, 80 AND OVER; ATROPHY; BRAIN; COGNITION DISORDERS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PRAVASTATIN;

EID: 77957266306     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f25f06     Document Type: Article

References (39)

1. Gouw AA, van der Flier WM, Fazekas F, et al. Progression of white matter hyperintensities and incidence of new la-cunes over a 3-year period: the Leukoaraiosis and Disability Study. Stroke 2008;39:1414-1420.
2. Knopman DS, Mosley TH, Catellier DJ, Sharrett AR. Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 2005;65:876-881.
3. Meyer JS, Rauch GM, Crawford K, et al. Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry 1999;14:1050-1061.
4. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997;28:652-659.
5. De Groot JC, de Leeuw FE, Oudkerk M, et al. Periven-tricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 2002;52:335-341.
6. Kramer JH, Mungas D, Reed BR, et al. Longitudinal MRI and cognitive change in healthy elderly. Neuropsychology 2007;21:412-418.
7. Van Den Heuvel DM, ten Dam VH, de Craen AJ, et al. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry 2006;77:149-153.
8. Ikram MA, Vrooman HA, Vernooij MW, et al. Brain tissue volumes in relation to cognitive function and risk of dementia. Neurobiol Aging Epub 2008 May 22.
9. Kuller LH, Lopez OL, Newman A, et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology 2003;22:13-22.
10. Whitwell JL, Przybelski SA, Weigand SD, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007;130:1777-1786.
11. Jongen C, van der GJ, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia 2007;50:1509-1516.
12. Kumar R, Anstey KJ, Cherbuin N, Wen W, Sachdev PS. Association of type 2 diabetes with depression, brain atrophy, and reduced fine motor speed in a 60-to 64-year-old community sample. Am J Geriatr Psychiatry 2008;16: 989-998.
13. Manschot SM, Brands AM, van der GJ, et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006;55:1106-1113.
14. Van Harten B, Oosterman J, Muslimovic D, van Loon BJ, Scheltens P, Weinstein HC. Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. Age Ageing 2007;36:164-170. (Pubitemid 46455395)
15. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 2001;24:366-370.
16. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000;160:174-180.
17. Hassing LB, Grant MD, Hofer SM, et al. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 2004;10:599-607.
18. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004;63:658-663.
19. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005;64:1704-1711.
20. Vermeer SE, den HT, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003;34:392-396. (Pubitemid 36206336)
21. Van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koud-staal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan Study. Stroke 2008;39:2712-2719.
22. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER): PROSPER Study Group: PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999;84:1192-1197.
23. Admiraal-Behloul F, van den Heuvel DM, Olofsen H, et al. Fully automatic segmentation of white matter hyperin-tensities in MR images of the elderly. Neuroimage 2005; 28:607-617.
24. Van Der Flier WM, van den Heuvel DM, Weverling-Rijnsburger AW, et al. Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann Neurol 2002;52:62-67.
25. Van Den Heuvel DM, dmiraal-Behloul F, ten Dam VH, et al. Different progression rates for deep white matter hyper-intensities in elderly men and women. Neurology 2004; 63:1699-1701.
26. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 2004;26:1044-1080.
27. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999;16:93-112.
28. Houx PJ, Jolles J, Vreeling FW. Stroop interference: aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 1993;19:209-224.
29. Klein M, Ponds RW, Houx PJ, Jolles J. Effect of test duration on age-related differences in Stroop interference. J Clin Exp Neuropsychol 1997;19:77-82.
30. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults: The Cardiovascular Health Study. Stroke 1994;25: 318-327.
31. Manschot SM, Biessels GJ, de Valk H, et al. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007;50:2388-2397.
32. Schmidt R, Launer LJ, Nilsson LG, et al. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004;53:687-692.
33. Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 2008;71:108-113.
34. Van Den Heuvel DM, ten Dam VH, de Craen AJ, et al. Measuring longitudinal white matter changes: comparison of a visual rating scale with a volumetric measurement. AJNR Am J Neuroradiol 2006;27:875-878.
35. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000;23:542-549.
36. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoi-nositides, and sodium-potassium-ATPase in the pathogen-esis of diabetic complications. N Engl J Med 1987;316: 599-606.
37. Van Den Berg E, de Craen AJ, Biessels GJ, Gussekloo J, West-endorp RG. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006;49:2015-2023.
38. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 2004;328:548.
39. Akisaki T, Sakurai T, Takata T, et al. Cognitive dysfunction associates with white matter hyperintensities and sub-cortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 2006;22: 376-384.